K. Deprince

A Randomized, Open-Label, Multicenter, Phase III Study of Epoetin Alfa Versus Best Standard of Care in Anemic Patients With Metastatic Breast Cancer Receiving Standard Chemotherapy.

B. Leyland-Jones, E. Vercammen, I. Bondarenko, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer.

N. Agarwal, D. Ye, A. Bjartell, 2019, The New England journal of medicine.

Apalutamide for metastatic, castration‐sensitive prostate cancer in the Japanese population: A subgroup analysis of the randomized, double‐blind, placebo‐controlled phase 3 TITAN study

K. Chi, H. Uemura, H. Uemura, 2020, International journal of urology : official journal of the Japanese Urological Association.

Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study.

E. Basch, N. Agarwal, D. Cella, 2019, The Lancet. Oncology.

Genetic Effect of Two APOA Repeat Polymorphisms (Kringle 4 and Pentanucleotide Repeats) on Plasma Lp(a) Levels in American Samoans

R. Ferrell, L. Bausserman, M. Kamboh, 2001, Human biology.

Androgen receptor (AR) aberrations in patients (Pts) with metastatic castration-sensitive prostate cancer (mCSPC) treated with apalutamide (APA) plus androgen deprivation therapy (ADT) in TITAN

A. Wyatt, N. Agarwal, F. Feng, 2019, Annals of Oncology.

Abstract S5-07: A randomized, open-label, multicenter, phase 3 study of epoetin alfa (EPO) plus standard supportive care versus standard supportive care in anemic patients with metastatic breast cancer (MBC) receiving standard chemotherapy

B. Leyland-Jones, K. Lakshmaiah, E. Vercammen, 2015 .

Pregnancy interruption after second trimester diagnosis of fetal structural anomalies: the New Jersey Fetal Abnormalities Registry.

C. Ananth, S. Marcella, J. Smulian, 2005, American journal of obstetrics and gynecology.

Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (FGFRalt).

R. Huddart, S. Park, J. Ku, 2023, Journal of Clinical Oncology.

Abiraterone acetate (AA) plus prednisone (P) 5 mg QD in metastatic castration-naïve prostate cancer (mCNPC): Detailed safety analyses from the LATITUDE phase 3 trial.

Y. Park, A. Bjartell, D. Olmos, 2018 .